Unlocking Insulin Resistance: Your Path to a Healthier Life!

Unlocking Insulin Resistance: Understanding the key to managing blood sugar levels and improving overall health. Take control of your journey towards a healthier life by addressing insulin resistance and its impact on your well-being

Unlocking Insulin Resistance: Your Path to a Healthier Life!

Insulin resistance (IR) is a condition in which cells in the body, particularly in the liver, muscles, and adipose tissue, fail to respond effectively to insulin. This leads to increased insulin production by the pancreas to compensate for reduced glucose uptake, eventually resulting in hyperinsulinaemia and dysregulated glucose metabolism [1,2]. Chronic IR is a key factor in the development of metabolic disorders such as type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), non‐alcoholic fatty liver disease (NAFLD), and polycystic ovary syndrome (PCOS) [1,2].

Insulin normally binds to its receptor on target cells, initiating a signalling cascade that promotes glucose uptake via glucose transporters. In IR, multiple disruptions occur in this pathway, including defects in insulin receptor substrate (IRS) activation due to inflammatory markers and lipid accumulation, inhibition of the metabolic pathways crucial for glucose uptake and glycogen synthesis, and increased specific phosphorylation that reduces insulin receptor sensitivity [1,2].

Mitochondria play a critical role in cellular energy metabolism. Dysfunctional mitochondria contribute to IR by increasing reactive oxygen species (ROS) production, which damages insulin signalling proteins, reduces energy generation, impairs cellular glucose uptake, and promotes lipid accumulation—leading to lipotoxicity and metabolic dysfunction [3].

In IR, excessive nutrient intake and inflammation trigger metabolic stress, leading to activation of the unfolded (Brocken) proteins, which impairs insulin signalling by increasing inflammatory markers and disrupting lipid balance, thereby contributing to systemic IR [4].

Chronic low‐grade inflammation plays a significant role in IR pathogenesis. Key inflammatory mediators include tumour necrosis factor (TNF‐α), which inhibits insulin signalling and promotes lipid accumulation. Another protein, interleukin‐6 (IL-6), under chronic stress, signals the liver to produce extra glucose and reduces insulin sensitivity in muscles. In addition, the inflammatory protein C-reactive protein (CRP) serves as a marker of systemic inflammation linked to IR and cardiovascular risk [4,12].

Certain genetic variants are associated with IR, particularly those affecting insulin receptor function and glucose metabolism. Epigenetic modifications, such as DNA methylation and histone acetylation, also contribute by altering gene expression in response to environmental factors [14].

Having too much fat—especially around your organs—can make it harder for your body to use insulin properly. This happens because extra fat releases substances that block insulin, disrupt hormone balance, and attract immune cells that cause inflammation [13].

A diet high in refined carbohydrates, saturated fats, and added sugars contributes to IR by inducing frequent insulin spikes, leading to pancreatic β-cell exhaustion, promoting alterations in gut microbiota, increasing gut permeability and systemic inflammation, and reducing fibre intake—each of which is associated with impaired glucose metabolism [5,6]. Lack of exercise reduces glucose uptake by skeletal muscles, leading to a reduction in both the quality and quantity of glucose receptors, impaired insulin-stimulated glucose transport, and decreased mitochondrial function, thereby exacerbating oxidative stress and metabolic dysfunction [3].

Alterations in gut microbiota composition affect IR through increased production of lipopolysaccharides (LPS), which trigger inflammation, decreased short-chain fatty acid (SCFA) production that impairs glucose metabolism, and altered bile acid metabolism that affects insulin sensitivity [11].

IR is the primary driver of T2DM development, characterised by β-cell dysfunction and failure due to chronic hyperinsulinaemia and persistent hyperglycaemia, leading to vascular and neurological complications. It contributes to cardiovascular disease through increased triglyceride levels, reduced HDL cholesterol, endothelial dysfunction, arterial stiffness, and elevated blood pressure due to hyperinsulinaemia-induced sodium retention. Hepatic insulin resistance leads to excessive fat accumulation in the liver, progressing to steatohepatitis and fibrosis. IR in the brain, often termed “Type 3 Diabetes,” is linked to amyloid plaque accumulation and neuroinflammation [2,4].

Several therapeutic strategies aim to improve insulin sensitivity and reduce the risk of complications associated with insulin resistance. These interventions include lifestyle modifications, pharmacological treatments, and emerging therapeutic approaches targeting the molecular mechanisms underlying IR [6].

Lifestyle modifications remain the first-line intervention for managing insulin resistance. A balanced diet rich in whole grains, fibre, lean proteins, and healthy fats can improve insulin sensitivity. Reducing processed carbohydrates, added sugars, and saturated fats helps regulate blood glucose levels and reduce inflammation. The Mediterranean diet and low-carbohydrate diets have shown significant benefits in improving metabolic health and insulin sensitivity. Regular physical activity, including both aerobic and resistance training, enhances glucose uptake by muscles and improves mitochondrial function. Moderate-intensity exercise, such as brisk walking, cycling, or strength training, is particularly effective in increasing the quality and quantity of glucose receptors and improving insulin signalling. Weight loss—even by 5–10% of body weight—can significantly reduce insulin resistance by decreasing visceral fat, improving lipid metabolism, and restoring normal adipokine balance [6].

Pharmacological treatments play a crucial role in managing insulin resistance, particularly for individuals with prediabetes, type 2 diabetes, or metabolic syndrome. Metformin is the most widely prescribed insulin-sensitising drug; it works by reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving mitochondrial function [7]. Thiazolidinediones (TZDs), such as pioglitazone, improve insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which regulates lipid metabolism and reduces inflammation in adipose tissue, although these drugs are associated with weight gain and fluid retention [10]. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, enhance insulin secretion, suppress appetite, and promote weight loss, making them beneficial for patients with obesity and insulin resistance [8]. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin, reduce blood glucose levels by promoting urinary glucose excretion, leading to improved insulin sensitivity and cardiovascular benefits [9].

Several emerging therapies target molecular pathways involved in insulin resistance. Anti-inflammatory agents, such as salicylates and cytokine inhibitors, aim to reduce chronic inflammation and improve insulin signalling. Targeting mitochondrial function through agents like nicotinamide riboside and coenzyme Q10 may enhance energy metabolism and reduce oxidative stress. Gut microbiome-based therapies, including probiotics, prebiotics, and faecal microbiota transplantation, are being explored to restore a healthy gut microbiota balance and improve metabolic function. Research on gene therapy and RNA-based therapeutics aims to modify gene expression related to insulin resistance, although these treatments are still in the early stages of development [5,14].

A multidisciplinary approach that combines lifestyle modifications, pharmacological interventions, and emerging therapies is essential for the effective management of insulin resistance. Personalised treatment strategies based on genetic, metabolic, and lifestyle factors can improve long-term outcomes and reduce the risk of developing severe metabolic disorders such as type 2 diabetes and cardiovascular disease [6,14].

References

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846.

2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–194.

3. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307(5708):384–387.

4. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.

5. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546–1558.

6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.

7. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.

8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.

9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.

10. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.

11. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772.

12. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.

13. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–445.

14. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363(24):2339–2350.